July 25, 2017 / 12:25 PM / 2 months ago

BRIEF-Seattle Genetics Inc says Health Canada has issued a non-conditional marketing authorization for use ofadcetris

July 25 (Reuters) - Seattle Genetics Inc:

* Seattle Genetics Inc says Health Canada has issued a non-conditional marketing authorization for use ofadcetris

* Seattle Genetics - Adcetris approval for post-asct consolidation treatment of patients with Hodgkin Lymphoma at increased risk of relapse or progression

* Seattle Genetics - Health Canada’s approval for adcetris indication based on positive phase 3 clinical trial results Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below